Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies
- 1 September 2011
- journal article
- case report
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 104 (1-2) , 167-173
Abstract
No abstract availableKeywords
Funding Information
- NHLBI (1R41HL093956-01, RO1HL085800)
- UB Office of the Vice President for Research (GDV)
This publication has 37 references indexed in Scilit:
- Malignant hyperthermiaOrphanet Journal of Rare Diseases, 2007
- Mutations inRYR1in malignant hyperthermia and central core diseaseHuman Mutation, 2006
- In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin‐induced adverse effectsArthritis Care & Research, 2006
- Genetic risk factors associated with lipid‐lowering drug‐induced myopathiesMuscle & Nerve, 2006
- The Sensitivity and Specificity of the Caffeine-Halothane Contracture TestAnesthesiology, 1998
- A Genome Wide Search for Susceptibility Loci in Three European Malignant Hyperthermia PedigreesHuman Molecular Genetics, 1997
- Malignant-Hyperthermia Susceptibility Is Associated with a Mutation of the a1-Subunit of the Human Dihydropyridine-Sensitive L-Type Voltage-Dependent Calcium-Channel Receptor in Skeletal MuscleThe American Journal of Human Genetics, 1997
- Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1.1995
- Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17qGenomics, 1992
- Molecular basis of AMP deaminase deficiency in skeletal muscle.Proceedings of the National Academy of Sciences, 1992